Pain News and Research

Latest Pain News and Research

Research finds link between opioid-sparing technique and reduced progression of prostate cancer

Research finds link between opioid-sparing technique and reduced progression of prostate cancer

Utah researchers discover naturally occurring genetic variation that cause inflammatory arthritis

Utah researchers discover naturally occurring genetic variation that cause inflammatory arthritis

Congressional lawmakers and political opponents stake out health law positions, strategies

Congressional lawmakers and political opponents stake out health law positions, strategies

Scientists continue work to end chemotherapy pain

Scientists continue work to end chemotherapy pain

NYSE publicly traded industry selects EPGL's advanced technologies for development

NYSE publicly traded industry selects EPGL's advanced technologies for development

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

Auxilium doses first patient in CCH Phase 2b study for treatment frozen shoulder syndrome

Duke research team develops better recipe for synthetic replacement cartilage in joints

Duke research team develops better recipe for synthetic replacement cartilage in joints

Prescription drug misuse and driving after using drugs on the rise among Ontario students

Prescription drug misuse and driving after using drugs on the rise among Ontario students

Findings could point the way to new vaccines to prevent Mycobacterium tuberculosis

Findings could point the way to new vaccines to prevent Mycobacterium tuberculosis

Study reports increased risk of death in patients receiving anesthesia drug etomidate for surgery

Study reports increased risk of death in patients receiving anesthesia drug etomidate for surgery

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Methodology needed to diagnose quality of life of individual cancer patients or survivors

Methodology needed to diagnose quality of life of individual cancer patients or survivors

Standardized research approaches needed for developing new treatments for neurofibromatosis

Standardized research approaches needed for developing new treatments for neurofibromatosis

Viewpoints: Problems with the 'doc fix;' a lame budget deal; concerns about changes in doctor training

Viewpoints: Problems with the 'doc fix;' a lame budget deal; concerns about changes in doctor training

Moberg announces positive results from phase ll study of MOB-015 for treatment of nail fungus

Moberg announces positive results from phase ll study of MOB-015 for treatment of nail fungus

Breast cancer survivors taking AIs may experience reduction in joint pain on exercising

Breast cancer survivors taking AIs may experience reduction in joint pain on exercising

Brazilian study provides evidence to support effectiveness of Tecta in erosive GERD

Brazilian study provides evidence to support effectiveness of Tecta in erosive GERD

Over-use of staging procedures more prevalent in younger, early-stage breast cancer patients

Over-use of staging procedures more prevalent in younger, early-stage breast cancer patients

Women treated with breast cancer drugs can ease joint pain by engaging in exercise

Women treated with breast cancer drugs can ease joint pain by engaging in exercise

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.